journal
https://read.qxmd.com/read/38824222/dynll1-accelerates-cell-cycle-via-ilf2-cdk4-axis-to-promote-hepatocellular-carcinoma-development-and-palbociclib-sensitivity
#21
JOURNAL ARTICLE
Yuechen Liu, Zhenkang Li, Jinchao Zhang, Wei Liu, Shenyuan Guan, Yizhi Zhan, Yuan Fang, Yongsheng Li, Haijun Deng, Zhiyong Shen
BACKGROUND: Disorder of cell cycle represents as a major driver of hepatocarcinogenesis and constitutes an attractive therapeutic target. However, identifying key genes that respond to cell cycle-dependent treatments still facing critical challenges in hepatocellular carcinoma (HCC). Increasing evidence indicates that dynein light chain 1 (DYNLL1) is closely related to cell cycle progression and plays a critical role in tumorigenesis. In this study, we explored the role of DYNLL1 in the regulation of cell cycle progression in HCC...
June 1, 2024: British Journal of Cancer
https://read.qxmd.com/read/38822146/epithelial-mesenchymal-transition-status-is-a-remarkable-biomarker-for-the-combination-treatment-with-avutometinib-and-defactinib-in-kras-mutated-non-small-cell-lung-cancer
#22
JOURNAL ARTICLE
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Koichi Takayama, Toshiyuki Sakai
BACKGROUND: Recent therapeutic strategies for KRAS-mutated cancers that inhibit the MAPK pathway have attracted considerable attention. The RAF/MEK clamp avutometinib (VS-6766/CH5126766/RO5126766/CKI27) is promising for patients with KRAS-mutated cancers. Although avutometinib monotherapy has shown clinical activity in patients with KRAS-mutated cancers, effective combination strategies will be important to develop. METHODS: Using a phosphorylation kinase array kit, we explored the feedback mechanism of avutometinib in KRAS-mutated NSCLC cells, and investigated the efficacy of combining avutometinib with inhibitors of the feedback signal using in vitro and in vivo experiments...
May 31, 2024: British Journal of Cancer
https://read.qxmd.com/read/38822145/pdzk1-confers-sensitivity-to-sunitinib-in-clear-cell-renal-cell-carcinoma-by-suppressing-the-pdgfr-%C3%AE-pathway
#23
JOURNAL ARTICLE
Haibo Wang, Lijie Zhang, Hua Liu, Yumeng Yang, Wenxiu Lu, Xuedi Cao, Xiaomei Yang, Qiong Qin, Ran Song, Duiping Feng, Songlin Wang, Tao Bai, Junqi He
BACKGROUND: Sunitinib has emerged as the primary treatment for advanced or metastatic clear cell renal cell carcinoma (ccRCC) due to its significant improvement in patients' average survival time. However, drug resistance and adverse effects of sunitinib pose challenges to its clinical benefits. METHODS: The differentially expressed genes (DEGs) associated with sunitinib sensitivity and resistance in ccRCC were investigated. Cell counting kit-8, plate colony formation, flow cytometry and subcutaneous xenograft tumor model assays were employed to explore the effects of PDZK1 on ccRCC...
May 31, 2024: British Journal of Cancer
https://read.qxmd.com/read/38806726/nuclear-factor-%C3%AE%C2%BAb-activation-by-transforming-growth-factor-%C3%AE-1-drives-tumour-microenvironment-mediated-drug-resistance-in-neuroblastoma
#24
JOURNAL ARTICLE
Kévin Louault, Laurence Blavier, Men-Hua Lee, Rebekah J Kennedy, G Esteban Fernandez, Bruce R Pawel, Shahab Asgharzadeh, Yves A DeClerck
BACKGROUND: Intrinsic and extrinsic factors in the tumour microenvironment (TME) contribute to therapeutic resistance. Here we demonstrate that transforming growth factor (TGF)-β1 produced in the TME increased drug resistance of neuroblastoma (NB) cells. METHODS: Human NB cell lines were tested in vitro for their sensitivity to Doxorubicin (DOX) and Etoposide (ETOP) in the presence of tumour-associated macrophages (TAM) and mesenchymal stromal cells/cancer-associated fibroblasts (MSC/CAF)...
May 28, 2024: British Journal of Cancer
https://read.qxmd.com/read/38806725/the-road-to-tailored-adjuvant-chemotherapy-for-all-four-non-pancreatic-periampullary-cancers-an-international-multimethod-cohort-study
#25
JOURNAL ARTICLE
Bas A Uijterwijk, Daniël H Lemmers, Michele Ghidini, Johanna W Wilmink, Alberto Zaniboni, Giuseppe Kito Fusai, Alessandro Zerbi, Bas Groot Koerkamp, Misha Luyer, Poya Ghorbani, Roberto Salvia, Steven White, Benedetto Ielpo, Brian K P Goh, Ugo Boggi, Geert Kazemier, Michael G House, Vasileios K Mavroeidis, Bergthor Björnsson, Michele Mazzola, Mario Serradilla, Dimitris Korkolis, Adnan Alseidi, Keith J Roberts, Zahir Soonawalla, Patrick Pessaux, William E Fisher, Sharnice Koek, Tara S Kent, Miljana Vladimirov, Louisa Bolm, Nigel Jamieson, Raffaele Dalla Valle, Jorg Kleeff, Alessandro Mazzotta, Miguel Angel Suarez Muñoz, Santiago Sánchez Cabús, Chad G Ball, Adam C Berger, Clarissa Ferarri, Marc G Besselink, Mohammed Abu Hilal
BACKGROUND: Despite differences in tumour behaviour and characteristics between duodenal adenocarcinoma (DAC), the intestinal (AmpIT) and pancreatobiliary (AmpPB) subtype of ampullary adenocarcinoma and distal cholangiocarcinoma (dCCA), the effect of adjuvant chemotherapy (ACT) on these cancers, as well as the optimal ACT regimen, has not been comprehensively assessed. This study aims to assess the influence of tailored ACT on DAC, dCCA, AmpIT, and AmpPB. PATIENTS AND METHODS: Patients after pancreatoduodenectomy for non-pancreatic periampullary adenocarcinoma were identified and collected from 36 tertiary centres between 2010 - 2021...
May 28, 2024: British Journal of Cancer
https://read.qxmd.com/read/38806724/parp-inhibition-leads-to-synthetic-lethality-with-key-splicing-factor-mutations-in-myelodysplastic-syndromes
#26
JOURNAL ARTICLE
Fangliang Zhang, Jianai Sun, Lei Zhang, Ruiqi Li, Yanzhen Wang, Huichao Geng, Chao Shen, Ling Li, Liang Chen
BACKGROUND: Splicing factors are frequently mutated in patients with myelodysplastic syndromes and acute myeloid leukaemia. Recent studies have revealed convergent molecular defects caused by splicing factor mutations, among which R-loop dysregulation and resultant genome instability are suggested as contributing factors to disease progression. On the other hand, understanding how mutant cells survive upon aberrant R-loop formation and genome instability is essential for developing novel therapeutics...
May 28, 2024: British Journal of Cancer
https://read.qxmd.com/read/38802672/outdoor-air-pollution-and-risk-of-incident-adult-haematologic-cancer-subtypes-in-a-large-us-prospective-cohort
#27
JOURNAL ARTICLE
W Ryan Diver, Lauren R Teras, Emily L Deubler, Michelle C Turner
BACKGROUND: Outdoor air pollution and particulate matter (PM) are classified as Group 1 human carcinogens for lung cancer. Pollutant associations with haematologic cancers are suggestive, but these cancers are aetiologically heterogeneous and sub-type examinations are lacking. METHODS: The American Cancer Society Cancer Prevention Study-II Nutrition Cohort was used to examine associations of outdoor air pollutants with adult haematologic cancers. Census block group level annual predictions of particulate matter (PM2...
May 27, 2024: British Journal of Cancer
https://read.qxmd.com/read/38796599/death-receptors-4-5-mediate-tumour-sensitivitnot-applicably-to-natural-killer-cell-mediated-cytotoxicity-in-mismatch-repair-deficient-colorectal-cancer
#28
JOURNAL ARTICLE
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liangping Xia
BACKGROUND: Identifying the target of natural killer (NK) cells in colorectal cancer (CRC) is critical for optimising the clinical use of NK cell-mediated immunotherapy. Mismatch repair deficiency (dMMR) is associated with high immune cell infiltration and MHC Class I defects. Whether dMMR CRC responses to NK cell therapy remains unclear. METHODS: MLH1, DR4, and DR5 knockout cell lines were established using CRISPR-Cas9 system. NK92-MI or NK cell isolated from BABL/C mice were used as effector cells against tumour cells...
May 25, 2024: British Journal of Cancer
https://read.qxmd.com/read/38796598/oncofetal-snrpe-promotes-hcc-tumorigenesis-by-regulating-the-fgfr4-expression-through-alternative-splicing
#29
JOURNAL ARTICLE
Qipeng Wu, Ruyan Liao, Chunmeng Miao, Muhammad Hasnat, Le Li, Lixin Sun, Xinru Wang, Ziqiao Yuan, Zhenzhou Jiang, Luyong Zhang, Qinwei Yu
BACKGROUND: Due to insufficient knowledge about key molecular events, Hepatocellular carcinoma (HCC) lacks effective treatment targets. Spliceosome-related genes were significantly altered in HCC. Oncofetal proteins are ideal tumor therapeutic targets. Screening of differentially expressed Spliceosome-related oncofetal protein in embryonic liver development and HCC helps discover effective therapeutic targets for HCC. METHODS: Differentially expressed spliceosome genes were analysis in fetal liver and HCC through bioinformatics analysis...
May 25, 2024: British Journal of Cancer
https://read.qxmd.com/read/38783165/metastasis-associated-fibroblasts-in-peritoneal-surface-malignancies
#30
REVIEW
Cristiano Ramos, Vasileios Gerakopoulos, Rudolf Oehler
Over decades, peritoneal surface malignancies (PSMs) have been associated with limited treatment options and poor prognosis. However, advancements in perioperative systemic chemotherapy, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) have significantly improved clinical outcomes. PSMs predominantly result from the spread of intra-abdominal neoplasia, which then form secondary peritoneal metastases. Colorectal, ovarian, and gastric cancers are the most common contributors...
May 23, 2024: British Journal of Cancer
https://read.qxmd.com/read/38778221/reply-to-qiao-et-al
#31
LETTER
Zibin Chen, Kaixin Lin, Huichuan Yu
No abstract text is available yet for this article.
May 22, 2024: British Journal of Cancer
https://read.qxmd.com/read/38778220/autoimmune-conditions-and-gastric-cancer-risk-in-a-population-based-study-in-the-united-kingdom
#32
JOURNAL ARTICLE
John D Murphy, Shahinaz M Gadalla, Lesley A Anderson, Charles S Rabkin, Chris R Cardwell, Minkyo Song, M Constanza Camargo
BACKGROUND: Although overall incidence of gastric cancer is decreasing, incidence has been increasing among young people in some Western countries. This trend may stem from the increase in autoimmune conditions. METHODS: A nested case-control study of gastric cancer in UK Clinical Practice Research Datalink. Up to ten cancer-free controls were matched to cases by age and sex. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for associations between analyzable autoimmune conditions (n = 34) and gastric cancer with Bonferroni correction...
May 22, 2024: British Journal of Cancer
https://read.qxmd.com/read/38773253/re-reply-to-rio-vilari%C3%A3-o-and-colleagues-article-and-misconception-about-yap1-ser-397-phosphorylation-function
#33
LETTER
Rafael Rosell
No abstract text is available yet for this article.
May 21, 2024: British Journal of Cancer
https://read.qxmd.com/read/38769450/efficacy-effectiveness-analysis-on-survival-in-a-population-based-real-world-study-of-braf-mutated-metastatic-colorectal-cancer-patients-treated-with-encorafenib-cetuximab
#34
JOURNAL ARTICLE
Koen Zwart, Sietske C M W van Nassau, Frederieke H van der Baan, Miriam Koopman, Petur Snaebjornsson, Anna J van Gestel, Geraldine R Vink, Jeanine M L Roodhart
BACKGROUND: Encorafenib-cetuximab has been approved for pretreated BRAFV600E -mutated metastatic colorectal cancer (mCRC) patients based on efficacy demonstrated in the randomized phase III BEACON trial. The aim of this real-world effectiveness study is to improve knowledge on the generalizability of trial results. METHODS: This population-based real-world study includes all mCRC patients in the Netherlands treated with encorafenib-cetuximab since approval. Individual patient data and pathology reports were collected...
May 20, 2024: British Journal of Cancer
https://read.qxmd.com/read/38762674/hla-a-tertiary-lymphoid-structures-with-reactivated-tumor-infiltrating-lymphocytes-are-associated-with-a-positive-immunotherapy-response-in-esophageal-squamous-cell-carcinoma
#35
JOURNAL ARTICLE
Dandan Zhang, Dongxian Jiang, Liping Jiang, Jiakang Ma, Xiaobing Wang, Xingyu Xu, Ziqiang Chen, Mengping Jiang, Wenjing Ye, Jie Wang, Weida Meng, Wenqing Qiu, Yingyong Hou, Jing Huang, Yuchen Jiao, Yun Liu, Zhihua Liu
BACKGROUND: Immune checkpoint blockade (ICB) therapy provides remarkable clinical benefits for multiple cancer types. However, the overall response rate to ICB therapy remains low in esophageal squamous cell carcinoma (ESCC). This study aimed to identify biomarkers of ICB therapy for ESCC and interrogate its potential clinical relevance. METHODS: We investigated gene expression in 42 treatment-naïve ESCC tumor tissues and identified differentially expressed genes, tumor-infiltrating lymphocytes and immune-related genes signatures associated with differential immunotherapy responses...
May 18, 2024: British Journal of Cancer
https://read.qxmd.com/read/38760445/the-association-between-tumour-heterogeneity-and-immune-evasion-mechanisms-in-hepatocellular-carcinoma-and-its-clinical-implications
#36
REVIEW
Kaina Chen, Timothy W H Shuen, Pierce K H Chow
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. The emergence of combination therapy, atezolizumab (anti-PDL1, immune checkpoint inhibitor) and bevacizumab (anti-VEGF) has revolutionised the management of HCC. Despite this breakthrough, the best overall response rate with first-line systemic therapy is only about 30%, owing to intra-tumoural heterogeneity, complex tumour microenvironment and the lack of predictive biomarkers. Many groups have attempted to classify HCC based on the immune microenvironment and have consistently observed better outcomes in immunologically "hot" HCC...
May 17, 2024: British Journal of Cancer
https://read.qxmd.com/read/38760444/epigenetic-activation-of-sox11-is-associated-with-recurrence-and-progression-of-ductal-carcinoma-in-situ-to-invasive-breast-cancer
#37
JOURNAL ARTICLE
Warapen Treekitkarnmongkol, Vandna Shah, Kazuharu Kai, Hiroshi Katayama, Justin Wong, Farah A Ladha, Tristian Nguyen, Brian Menegaz, Wei Lu, Fei Yang, Barbara Mino, Ximing Tang, Mihai Gagea, Harsh Batra, Maria Gabriela Raso, Ignacio I Wistuba, Savitri Krishnamurthy, Sarah E Pinder, Elinor J Sawyer, Alastair M Thompson, Subrata Sen
BACKGROUND: Risk of recurrence and progression of ductal carcinoma in situ (DCIS) to invasive cancer remains uncertain, emphasizing the need for developing predictive biomarkers of aggressive DCIS. METHODS: Human cell lines and mouse models of disease progression were analyzed for candidate risk predictive biomarkers identified and validated in two independent DCIS cohorts. RESULTS: RNA profiling of normal mammary and DCIS tissues (n = 48) revealed that elevated SOX11 expression correlates with MKI67, EZH2, and DCIS recurrence score...
May 17, 2024: British Journal of Cancer
https://read.qxmd.com/read/38750116/reply-to-l-celio-et-al
#38
LETTER
Hiroko Minatogawa, Naoki Izawa, Takako Eguchi Nakajima
No abstract text is available yet for this article.
May 15, 2024: British Journal of Cancer
https://read.qxmd.com/read/38750115/recommendations-for-reporting-tissue-and-circulating-tumour-ct-dna-next-generation-sequencing-results-in-non-small-cell-lung-cancer
#39
REVIEW
Umberto Malapelle, Natasha Leighl, Alfredo Addeo, Dov Hershkovitz, Maximilian J Hochmair, Ola Khorshid, Florian Länger, Filippo de Marinis, Nir Peled, Brandon S Sheffield, Egbert F Smit, Santiago Viteri, Jürgen Wolf, Filippo Venturini, Richard M O'Hara, Christian Rolfo
Non-small cell lung cancer is a heterogeneous disease and molecular characterisation plays an important role in its clinical management. Next-generation sequencing-based panel testing enables many molecular alterations to be interrogated simultaneously, allowing for comprehensive identification of actionable oncogenic drivers (and co-mutations) and appropriate matching of patients with targeted therapies. Despite consensus in international guidelines on the importance of broad molecular profiling, adoption of next-generation sequencing varies globally...
May 15, 2024: British Journal of Cancer
https://read.qxmd.com/read/38750114/synergistic-antitumor-activity-by-dual-blockade-of-ccr1-and-cxcr2-expressed-on-myeloid-cells-within-the-tumor-microenvironment
#40
JOURNAL ARTICLE
Hideyuki Masui, Kenji Kawada, Yoshiro Itatani, Hideyo Hirai, Yuki Nakanishi, Yoshiyuki Kiyasu, Keita Hanada, Michio Okamoto, Wataru Hirata, Yasuyo Nishikawa, Naoko Sugimoto, Takuya Tamura, Yoshiharu Sakai, Kazutaka Obama
BACKGROUND: Chemokine signaling within the tumor microenvironment can promote tumor progression. Although CCR1 and CXCR2 on myeloid cells could be involved in tumor progression, it remains elusive what effect would be observed if both of those are blocked. METHODS: We employed two syngeneic colorectal cancer mouse models: a transplanted tumor model and a liver metastasis model. We generated double-knockout mice for CCR1 and CXCR2, and performed bone marrow (BM) transfer experiments in which sub-lethally irradiated wild-type mice were reconstituted with BM from either wild-type, Ccr1-/- , Cxcr2-/- or Ccr1-/- Cxcr2-/- mice...
May 15, 2024: British Journal of Cancer
journal
journal
23366
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.